SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-022573
Filing Date
2024-06-04
Accepted
2024-06-04 17:00:57
Documents
65
Period of Report
2024-04-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 789917
2 ex10-1.htm EX-10.1 222091
3 ex31-1.htm EX-31.1 19269
4 ex31-2.htm EX-31.2 19240
5 ex32-1.htm EX-32.1 7883
6 ex32-2.htm EX-32.2 7926
7 ex10-1_001.jpg GRAPHIC 24229
8 image_002.jpg GRAPHIC 2240
  Complete submission text file 0001493152-24-022573.txt   4537257

Data Files

Seq Description Document Type Size
9 XBRL SCHEMA FILE anix-20240430.xsd EX-101.SCH 29664
10 XBRL CALCULATION FILE anix-20240430_cal.xml EX-101.CAL 41646
11 XBRL DEFINITION FILE anix-20240430_def.xml EX-101.DEF 142232
12 XBRL LABEL FILE anix-20240430_lab.xml EX-101.LAB 252654
13 XBRL PRESENTATION FILE anix-20240430_pre.xml EX-101.PRE 208796
69 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 638519
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

IRS No.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: 10-Q | Act: 34 | File No.: 001-37492 | Film No.: 241019147
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)